Article Text

Download PDFPDF
Diagnostic utility of anti-Ro52 detection in systemic autoimmunity
  1. Manish Dugar1,
  2. Sally Cox1,
  3. Vidya Limaye1,
  4. Tom Paul Gordon2,
  5. Peter John Roberts-Thomson2
  1. 1Royal Adelaide Hospital, Adelaide, Australia
  2. 2Flinders Medical Centre, Adelaide, Australia
  1. Correspondence to Dr Manish Dugar, Department of Rheumatology, Level 4 Eleanor Harrald Building, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5042, Australia; manish.dugar{at}


Objectives To determine the prevalence and diagnostic utility of monospecific anti-Ro52 (defined as an immune response against Ro-52 antigen in the absence of reactivity to Ro-60 antigen) reactivity in selected autoimmune diseases.

Study design Stored diagnostic non-consecutive serum samples obtained from patients with systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), systemic sclerosis, idiopathic inflammatory myopathies (IIM), rheumatoid arthritis, primary biliary cirrhosis and mixed essential cryoglobulinaemia were analysed by line immunoassay to detect the presence of anti-Ro52 and other autoantibodies.

Results Monospecific anti-Ro52 reactivity was found in 51 (12.7%) of the 402 samples tested. Anti-Ro52 was the most common serological marker in patients with IIM (35/147, 23.8%) and co-occurred with anti-Jo1 (10/18, 55.6%; p=0.02). The prevalence of anti-Ro52 reactivity was significantly more than anti-Ro60 reactivity in patients with IIM, systemic sclerosis, primary biliary cirrhosis, mixed essential cryoglobulinemia and pSS. The mean signal intensity of anti-Ro52 reactivity was significantly higher in pSS than SLE and associated with rheumatoid factor positivity. The mean signal intensity of anti-Ro52 correlated with anti-Ro60 and anti-La in pSS and SLE.

Conclusions Monospecific anti-Ro52 reactivity is not disease specific but may be of importance in patients with IIM. Furthermore, as anti-Ro52 reactivity is more prevalent than anti-Ro60 reactivity in certain autoimmune conditions, specific testing for their distinction in clinical practice is recommended.

  • Ro52
  • Ro52 antigen
  • autoimmune diseases
  • myositis
  • diagnostic tests
  • rheumatology

Statistics from


  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Clinical Ethics Committee, Flinders Medical Centre, Adelaide, Australia.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.